5-mg Tamoxifen as Effective as 20 mg Daily in Early Localized Breast Cancer.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 1, p. 18
- By:
- Publication type:
- Article
Works matching IS 21644403 AND DT 2019 AND VI 9 AND IP 1
Results: 8
1
2
One Oncologist's Firsthand Experience with Serious Illness: What Your Patients Want.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 1, p. 1
- By:
- Publication type:
- Article
3
FDA Perspective: Reducing Cost, Increasing Access to Cancer Care.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 1, p. 1
- By:
- Publication type:
- Article
4
Checkpoint Inhibitor a New Approach to Jump-Start a Waning Response to CAR T-Cell Therapy.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 1, p. 21
- By:
- Publication type:
- Article
5
Brigatinib, Next-Generation ALK Inhibitor, Improves Survival versus Crizotinib in Patients with NSCLC and ALK Mutation.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 1, p. 17
- By:
- Publication type:
- Article
6
Researchers Identify First Mutation to Explain Resistance to Venetoclax.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 1, p. 14
- By:
- Publication type:
- Article
7
Identifying the Problem Is Key to Quality Improvement in Cancer Care.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 1, p. 10
- By:
- Publication type:
- Article
8
Paradigm Shift: Ibrutinib plus Rituximab Front-Line Therapy for Patients with CLL Under Age 70.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 1, p. 1
- By:
- Publication type:
- Article